Academic & Non-Profit

The Intact Proviral DNA Assay (IPDA) uses duplex droplet digital PCR (ddPCR) to quantify genomically intact HIV-1 proviruses. Dual-target detection (packaging signal and env RRE) distinguishes intact from defective genomes, enabling accurate HIV reservoir quantification.

• Detects intact proviruses capable of reactivation.
• Provides both intact and total proviral load in one assay.
• Applicable to HIV-1, SIV, and SHIV for preclinical models.
• Limit of detection: single intact provirus per million cells (dependent on input).

Applications: Longitudinal monitoring of intact reservoir size during latency-reversing agent studies, immune-based interventions, or functional cure trials.

Total HIV DNA qPCR quantifies all integrated HIV proviruses, intact or defective.

• Conserved gene targeting for broad subtype coverage.
• Suitable for PBMCs or tissue samples.
• High-throughput, low sample volume requirement.

Applications: Surrogate reservoir measurement in large-scale studies, vaccine trials, and early-treated cohorts. Often paired with IPDA or QVOA for comprehensive analysis.

The Cell-Associated HIV RNA assay measures HIV transcription within infected cells.

• Detects unspliced and/or multiply-spliced HIV RNA transcripts.
• DNase treatment ensures RNA-specific signal.
• Highly sensitive for ART-suppressed samples.

Applications: Evaluating latency reversal efficiency, monitoring transcriptional activity in block-and-lock strategies, and assessing pharmacodynamic effects of LRAs.

QVOA measures the frequency of resting CD4⁺ T cells harboring inducible, replication-competent HIV. Cells are stimulated in limiting dilution and monitored for viral outgrowth (p24 or HIV RNA detection) over 2–3 weeks.

• Reports infectious units per million cells (IUPM).
• Remains the gold standard for replication-competent reservoir detection.
• Can be paired with ultrasensitive p24 digital ELISA for improved sensitivity.

Applications: Baseline reservoir measurement in cure trials, verification of reservoir reduction, and confirmation of residual replication-competent virus post-intervention.

Bulk outgrowth assays stimulate large CD4⁺ T cell populations to recover replication-competent virus without limiting dilution.

• Provides isolates for phenotypic analysis (neutralization sensitivity, drug susceptibility).
• Useful for sequencing and resistance profiling.
• Not quantitative but effective for qualitative detection of replication-competent virus.

Applications: Characterizing latent viruses, evaluating bNAb sensitivity, and generating patient-derived isolates for therapeutic testing.

The Single Copy Assay detects plasma HIV RNA down to <1 copy/mL, enabling measurement of residual viremia below clinical detection limits.

• Requires large plasma input with ultracentrifugation.
• Targets conserved HIV regions for subtype-independent detection.
• Performed under GLP-like conditions to minimize contamination.

Applications: Monitoring residual viremia during suppressive ART, assessing antiviral effects of new therapies, and early detection of rebound during ATI.

Accelevir’s NGS platforms provide in-depth sequence analysis of HIV reservoirs and circulating virus.

• Near full-length proviral sequencing: Distinguishes intact from defective proviruses and maps clonal expansions.
• HIV-1 Env Long-Read Sequencing (EnvLRS): Profiles viral env diversity to predict broadly neutralizing antibody (bNAb) susceptibility.
• Supports drug resistance genotyping, integration site mapping, and longitudinal viral evolution studies.

Applications: Validating IPDA results, guiding bNAb therapy selection, identifying reservoir persistence mechanisms, and informing vaccine design.

Accelevir offers immunology assays to profile HIV-specific cellular and humoral responses.

• ELISpot / FluoroSpot: Quantifies antigen-specific T cell cytokine production (e.g., IFN-γ) in response to HIV peptides.
• Intracellular Cytokine Staining (ICS) by flow cytometry: Measures polyfunctional T cell responses and phenotypes.
• Neutralizing antibody assays: Evaluates breadth and potency of vaccine- or therapy-induced antibodies.
• Phenotyping: Identifies immune activation, exhaustion, and memory subsets.

Applications: Monitoring immune correlates of protection in vaccine trials, evaluating “kill” efficiency in kick-and-kill strategies, and tracking immune restoration post-intervention.